Why carry out this study?

Plasma volume status (PVS), an indication of the discrepancy between actual plasma volume (PV) and ideal PV, has been recently evaluated as a prognostic marker in patients with heart failure.

This trial was designed to determine whether a sodium-glucose cotransporter 2 (SGLT2) inhibitor (empagliflozin) affected the improvement of heart failure and PVS in patients after acute myocardial infarction (AMI) with congestive heart failure (CHF).

What was learned from the study?

Empagliflozin reduced not only the body weight but also PVS.

The results suggest that early SGLT2 inhibitor administration in patients with AMI, CHF, and T2DM can be effective in reducing the body weight and PVS.